Janika Viereck

Head of Research and Development

Idorsia Pharmaceuticals Ltd

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Janika Viereck is the Head of Research and Development at Cardior Pharmaceuticals GmbH in Germany. Her research focuses on heart failure, specifically through the development of innovative therapies such as CDR132L and the exploration of microRNAs and long non-coding RNAs in cardiovascular health. Recent articles highlight her work on novel treatment mechanisms and the efficacy of antisense therapies in preclinical and clinical settings.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Xiaoke Yin

King’s College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Janika Viereck

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.

Development of a Mechanism-Based Next-Generation Therapeutic for Heart Failure Derived From the Dark Genome.

AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes.

ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.

AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction.

CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.

Preclinical development of a miR-132 inhibitor for heart failure treatment

Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy.

Pleiotropic cardiac functions controlled by ischemia-induced lncRNA H19.

Collaborators (1)

Xiaoke Yin

Make your next move.